miR-17-92 exerts its inhibitory effect on the progression of CRC by reducing tumor angiogenesis which is achieved by targeting several tumor angiogenesis-inducing genes, including TGFBR2, HIF1α, and VEGFA, both in vivo and in vitro [50]. This evidence concerns the gene VEGFA and neoplasm.